@article {DemyanenkoPA701, author = {Natalya Demyanenko and Averbakh Mihail and Natalya Makaryants and Elena Vladimirova and Anna Egorova and Aminat Akhmedova}, title = {The role of nonspecific inflammation factors {\textendash} SA-A and pentraxin-3 in patients with respiratory sarcoidosis in different age groups}, volume = {58}, number = {suppl 65}, elocation-id = {PA701}, year = {2021}, doi = {10.1183/13993003.congress-2021.PA701}, publisher = {European Respiratory Society}, abstract = {Objective: To study the level of nonspecific inflammation factors {\textendash} SA-A and pentraxin-3 in patients with respiratory sarcoidosis in different age groups. Materials and methods: The survey included 74 patients with newly diagnosed and recurrent sarcoidosis aged under and over 40. The parameters of SA-A and pentraxin -3 in blood plasma were studied. The upper normal level for SA-A was set as 10 μg / ml, for pentraxin-3 - 2 ng / ml (according to the standard).Results: The level of pentraxin -3 in the age group under 40 with newly diagnosed sarcoidosis was 1.05 {\textpm} 0.09 ng / ml, in the age group over 40 the level was 1.0 {\textpm} 0 (within normal limits). In the group of patients with recurrent sarcoidosis its level was also within normal limits. When examining the SA-A level in the age group over 40 with newly diagnosed sarcoidosis, it was 15.9 {\textpm} 0.7 ng / ml, which was initially significantly higher than in the age group under 40. In the group with recurrent course of the disease the SA-A level was higher than normal in both age groups (13.7 {\textpm} 1.6 and 14.2 {\textpm} 1.7 ng / ml, respectively).Conclusion: In the study of blood serum, the level of pentraxin-3 remained unchanged regardless of age and course of sarcoidosis. Whereas the SA-A level was initially elevated in the group with a relapsing course of the disease. In the age group under 40 with newly diagnosed sarcoidosis its level was significantly higher than in the age group over 40.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA701.This abstract was presented at the 2021 ERS International Congress, in session {\textquotedblleft}Prediction of exacerbations in patients with COPD{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/58/suppl_65/PA701}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }